Core Insights - CRISPR Therapeutics' Casgevy, a one-shot gene therapy, received approval in late 2023 and early 2024 for sickle cell disease and transfusion-dependent beta-thalassemia in the US and Europe [1] - The partnership with Vertex Pharmaceuticals involves a 60:40 split of program costs and profits, with Vertex leading global development and commercialization [1] Sales Performance - Casgevy had a slow start in 2024, generating only $10 million in full-year product revenues for Vertex, but sales increased significantly to $30.4 million in Q2 2025, marking a 114.1% sequential increase [2][8] - Vertex estimates Casgevy sales to reach approximately $124.6 million in 2025 [2] Treatment Centers and Patient Engagement - Over 75 authorized treatment centers are active for Casgevy, with 115 patients completing their first cell collection as of June 2025 [3][8] Revenue Growth Potential - Increasing Casgevy sales could provide a stable revenue base for CRISPR Therapeutics, allowing for greater investment in its gene-editing pipeline and enhancing long-term growth prospects in the competitive cell and gene therapy market [4][8] Competitive Landscape - Other companies in the gene-editing space include Beam Therapeutics, which is developing BEAM-101 for sickle cell disease, and Intellia Therapeutics, which is advancing in vivo therapies for hereditary angioedema and transthyretin amyloidosis [5][6] Stock Performance and Valuation - CRISPR Therapeutics' shares have increased by 40.7% year-to-date, contrasting with a 0.7% decline in the industry [7] - The company's shares trade at a price-to-book value (P/B) ratio of 2.80, below the industry average of 3.15, but above its five-year mean of 2.38 [9] Earnings Estimates - Loss per share estimates for CRISPR Therapeutics for 2025 have widened from $5.58 to $6.22, while estimates for 2026 have narrowed from $4.30 to $4.03 [10]

FDA Regulation and Drug Approval - The FDA's drug and biological approvals, including gene therapies, are under scrutiny following the departure of Dr Assad [3] - The FDA commissioner aims to recalibrate standards for more efficient regulatory pathways, leveraging AI and big data to improve the drug approval process [10][11] - The industry anticipates the incoming head of the division handling biologics to share the same priorities of improving the FDA and facilitating innovation [12] - The FDA is considering approving rare disease therapies at the first sign of promise, recognizing the lack of meaningful disease-modifying options for these patients [19] Gene Therapy and Clinical Trials - A gene therapy from Sarepta Therapeutics for Duchenne muscular dystrophy faced safety concerns due to patient deaths, leading to a temporary halt of shipments [4][5] - Patient advocacy groups expressed devastation over losing the gene therapy option, which could potentially halt or reverse disease progression [6] - Acute liver failure was linked to the deaths of teenage boys in the Sarepta Therapeutics trial, potentially due to higher doses per kilogram in older patients [13][14] - AI can be embedded into clinical trials to simulate and explore avenues, potentially preventing patient deaths and improving the success rate of getting the right drugs to the right patients faster [16][17] Genomics and AI - The industry is excited about the potential of gene editing for common diseases like cardiovascular disease, building on the proof of concept in rare diseases [21] - CRISPR Therapeutics is developing gene editing therapies targeting genes involved in liver metabolism to address cardiovascular disease [22] - Advances in AI are unlocking new possibilities in genomics, enabling better target design, faster pre-clinical studies, and improved clinical trial design [30][31][32]

Core Insights - CRISPR Therapeutics reported a second-quarter 2025 loss of $2.40 per share, wider than the previous year's loss of $1.49, primarily due to a $96.3 million expense related to a collaboration with Sirius Therapeutics [1][6] - Adjusted loss, excluding special items, was $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47 [2] - Total revenues for the quarter were $0.89 million, significantly below the Zacks Consensus Estimate of $6.6 million, compared to $0.5 million in the same period last year [2] Financial Performance - CRISPR Therapeutics' stock fell over 8% in after-market trading following the wider-than-expected loss, continuing the downward trend in pre-market trading [3] - The stock has increased by 51% year-to-date, outperforming the industry growth of 2% [3] - Research and development expenses decreased by 13% year-over-year to $69.9 million, while general and administrative expenses fell by 3% to $18.9 million [8] Product Development and Sales - Casgevy, a CRISPR/Cas9 gene-edited therapy developed in partnership with Vertex Pharmaceuticals, saw sales of $30.4 million in Q2, up from $14.2 million in the previous quarter [5][6] - Over 75 treatment centers have been activated globally for Casgevy, with approximately 115 patients completing their first cell collection since its launch [6][7] - The company is advancing its CAR-T and in-vivo therapy pipelines, with updates expected later this year [10][11] Pipeline Expansion - CRISPR Therapeutics is developing two next-generation CAR-T therapy candidates, CTX112 and CTX131, currently in phase I/II studies [10] - The company is also studying in-vivo candidates CTX310 and CTX320, with promising early data showing significant reductions in LDL and triglyceride levels [11] - A collaboration with Sirius Therapeutics has diversified the pipeline into RNA therapeutics, with a focus on the investigational siRNA candidate SRSD107 [12][13] Financial Position - As of June 30, 2025, CRISPR Therapeutics had cash and marketable securities totaling $1.72 billion, down from $1.86 billion at the end of March 2025 [9]

Group 1: Earnings Performance - CRISPR Therapeutics reported a quarterly loss of $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47, and an improvement from a loss of $1.49 per share a year ago, representing an earnings surprise of +12.24% [1] - The company posted revenues of $0.89 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.45%, compared to year-ago revenues of $0.52 million [2] - Over the last four quarters, CRISPR Therapeutics has surpassed consensus EPS estimates three times [2] Group 2: Stock Performance and Outlook - CRISPR Therapeutics shares have increased approximately 42.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is -$1.35 on revenues of $8.89 million, and -$5.61 on revenues of $41.42 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5] - The unfavorable estimate revisions trend prior to the earnings release resulted in a Zacks Rank 5 (Strong Sell) for CRISPR Therapeutics, suggesting expected underperformance in the near future [6]

PART I: FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements (unaudited)](index=6&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) CRISPR Therapeutics reported a significant increase in net loss for H1 2025, primarily due to a substantial acquired R&D charge, alongside a decrease in cash and a shift to net cash used in operating activities Condensed Consolidated Balance Sheet Data (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $193,618 | $298,257 | | Marketable securities | $1,527,619 | $1,605,569 | | **Total Assets** | **$2,029,711** | **$2,242,034** | | Total current liabilities | $104,362 | $87,782 | | **Total Liabilities** | **$318,586** | **$309,954** | | **Total Shareholders' Equity** | **$1,711,125** | **$1,932,080** | Condensed Consolidated Statements of Operations (in thousands) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $892 | $517 | $1,757 | $1,021 | | Research and development | $69,894 | $80,165 | $142,378 | $156,338 | | Acquired in-process R&D | $96,253 | $— | $96,253 | $— | | Collaboration expense, net | $45,153 | $52,131 | $102,662 | $99,097 | | **Loss from operations** | **($229,324)** | **($151,260)** | **($377,748)** | **($291,848)** | | **Net loss** | **($208,549)** | **($126,408)** | **($344,545)** | **($242,999)** | | **Net loss per share — basic** | **($2.40)** | **($1.49)** | **($3.98)** | **($2.92)** | Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | ($167,827) | $14,170 | | Net cash provided by (used in) investing activities | $50,222 | ($224,705) | | Net cash provided by financing activities | $12,846 | $305,468 | | **(Decrease) increase in cash** | **($104,638)** | **$94,924** | - The company's May 2025 collaboration with Sirius Therapeutics resulted in a **$96.3 million** charge for acquired in-process research and development, comprising a **$25.0 million** upfront cash payment and **$71.3 million** in common shares issued to Sirius[83](index=83&type=chunk)[119](index=119&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=32&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the increased net loss in Q2 and H1 2025 primarily to the **$96.3 million** acquired R&D expense, while maintaining a strong liquidity position expected to fund operations for at least 24 months [Overview of Business and Programs](index=32&type=section&id=Overview%20of%20Business%20and%20Programs) CRISPR Therapeutics develops gene-based medicines across four core franchises, highlighted by the landmark approval of CASGEVY and advancements in CAR T, In Vivo, and siRNA therapies - **CASGEVY**, the first-ever approved CRISPR-based therapy, has received approvals in the U.S., E.U., Great Britain, and other countries for treating sickle cell disease and beta thalassemia[127](index=127&type=chunk) - The company is advancing next-generation allogeneic CAR T programs, **CTX112** and **CTX131**, for oncology and autoimmune indications, manufactured at its internal GMP facility[130](index=130&type=chunk) - In May 2025, the company entered a strategic collaboration with **Sirius Therapeutics** to jointly develop and commercialize **SRSD107**, a long-acting siRNA targeting Factor XI for thrombosis[139](index=139&type=chunk) [Results of Operations](index=41&type=section&id=Results%20of%20Operations) Net loss significantly increased in Q2 and H1 2025, primarily due to a **$96.3 million** acquired R&D charge, despite a decrease in R&D expenses Comparison of Results (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Loss** | **($208,549)** | **($126,408)** | **($344,545)** | **($242,999)** | | R&D Expenses | $69,894 | $80,165 | $142,378 | $156,338 | | Acquired In-process R&D | $96,253 | $— | $96,253 | $— | | Collaboration Expense, Net | $45,153 | $52,131 | $102,662 | $99,097 | - The **$96.3 million** acquired in-process R&D expense in Q2 2025 is entirely attributable to costs from the Sirius Agreement[168](index=168&type=chunk)[177](index=177&type=chunk) - The decrease in R&D expenses for Q2 2025 was primarily driven by a **$7.6 million** reduction in employee-related expenses and a **$2.8 million** decrease in sublicense and license fees[167](index=167&type=chunk)[169](index=169&type=chunk) [Liquidity and Capital Resources](index=44&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains a strong liquidity position with **$1.72 billion** in cash and equivalents, expected to fund operations for at least 24 months, supplemented by recent ATM offering proceeds - The company holds **$1,721.2 million** in cash, cash equivalents, and marketable securities as of **June 30, 2025**[181](index=181&type=chunk) - Existing cash is expected to fund operating expenses and capital expenditures for at least the next **24 months**[190](index=190&type=chunk) - From **June 30, 2025**, through the report's filing date, the company sold an additional **2.3 million shares** under its ATM program for aggregate proceeds of **$130.7 million**[185](index=185&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=50&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company assesses its exposure to market risks, including interest rates and foreign currency, as not material due to conservative investment strategies - The company does not believe it has material exposure to interest rate risk due to its conservative investment portfolio[203](index=203&type=chunk) - Exposure to foreign currency exchange rate risk, primarily Swiss Franc and British Pound, is not considered material, and no hedging transactions have been engaged[204](index=204&type=chunk) [Item 4. Controls and Procedures](index=50&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of **June 30, 2025**[207](index=207&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter ended **June 30, 2025**[208](index=208&type=chunk) PART II: OTHER INFORMATION [Item 1. Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no pending claims or actions likely to have a material adverse effect on its business, with no material developments since the last annual report - There are currently no claims or actions pending against the company that management believes are likely to have a material adverse effect on the business[209](index=209&type=chunk) [Item 1A. Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's previously disclosed risk factors have occurred since the Annual Report for FY2024 and the Q1 2025 Quarterly Report - No material changes to risk factors have occurred since the company's Annual Report for **FY2024** and the Quarterly Report for **Q1 2025**[211](index=211&type=chunk) [Item 5. Other Information](index=51&type=section&id=Item%205.%20Other%20Information) CEO Samarth Kulkarni adopted a Rule 10b5-1 trading plan on June 10, 2025, for the potential sale of up to **75,000** common shares - On **June 10, 2025**, CEO Samarth Kulkarni adopted a Rule 10b5-1 trading plan for the sale of up to **75,000** common shares, active through **March 31, 2026**[215](index=215&type=chunk)

[CRISPR Therapeutics Business Update and Q2 2025 Financial Results](index=1&type=section&id=CRISPR%20Therapeutics%20Business%20Update%20and%20Q2%202025%20Financial%20Results) [Business Highlights and Outlook](index=1&type=section&id=Business%20Highlights%20and%20Outlook) The company reports strong commercial and clinical program momentum, with key data updates expected and a solid cash position of approximately $1.7 billion - The company is experiencing momentum across its commercial and clinical programs, with several key milestones anticipated in the **second half of 2025**[2](index=2&type=chunk) - Maintains a strong balance sheet with approximately **$1.7 billion in cash**, cash equivalents, and marketable securities as of June 30, 2025[1](index=1&type=chunk) [Hemoglobinopathies and CASGEVY®](index=1&type=section&id=Hemoglobinopathies%20and%20CASGEVY%C2%AE) The commercial launch of CASGEVY® is progressing with 75 treatment centers activated globally and reimbursement agreements secured in 10 countries - Achieved the target of activating **75 authorized treatment centers (ATCs)** globally for CASGEVY®[3](index=3&type=chunk) - As of June 30, approximately **115 patients have completed cell collection**, and 29 patients have received CASGEVY® infusions, with 16 of those occurring in Q2[3](index=3&type=chunk) - Vertex has secured **reimbursement agreements for eligible patients in 10 countries**, including recent additions of Northern Ireland, Scotland, and Denmark[6](index=6&type=chunk) - Advancing next-generation approaches, including an anti-CD117 ADC and an in vivo editing platform, to expand the addressable patient population[6](index=6&type=chunk) [Immuno-Oncology and Autoimmune Disease Programs](index=2&type=section&id=Immuno-Oncology%20and%20Autoimmune%20Disease%20Programs) The company is advancing its next-generation CAR T candidates, with CTX112™ receiving RMAT designation and broad data updates expected in H2 2025 - CTX112, targeting CD19, received **Regenerative Medicine Advanced Therapy (RMAT) designation** from the FDA for relapsed or refractory follicular lymphoma and marginal zone lymphoma[6](index=6&type=chunk) - A Phase 1 trial of CTX112 is ongoing for autoimmune indications, including **systemic lupus erythematosus (SLE)**[6](index=6&type=chunk) - Broad updates for CTX112 in oncology and autoimmune disease are expected in **H2 2025**, with updates for the CTX131 program also expected in 2025[1](index=1&type=chunk)[6](index=6&type=chunk) [In Vivo Liver Editing Programs](index=2&type=section&id=In%20Vivo%20Liver%20Editing%20Programs) The in vivo pipeline shows progress with CTX310™ demonstrating significant reductions in triglycerides and LDL, with a full data presentation expected in H2 2025 CTX310™ Preliminary Phase 1 Data Highlights | Metric | Peak Reduction | | :--- | :--- | | Triglycerides (TG) | up to 82% | | Low-density lipoprotein (LDL) | up to 86% | - The company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the **second half of 2025**[1](index=1&type=chunk)[10](index=10&type=chunk) - A clinical trial for CTX320™, targeting the LPA gene, is ongoing, with an update expected in the **first half of 2026**[1](index=1&type=chunk)[10](index=10&type=chunk) [SRSD107 and Sirius Therapeutics Collaboration](index=4&type=section&id=SRSD107%20and%20Sirius%20Therapeutics%20Collaboration) A strategic collaboration with Sirius Therapeutics was initiated to co-develop siRNA therapies, with SRSD107 receiving EMA authorization for a Phase 2 trial - Entered a strategic collaboration with Sirius Therapeutics to jointly develop and commercialize siRNA therapies, beginning with SRSD107[10](index=10&type=chunk) - Received European Medicines Agency (EMA) authorization to initiate a **Phase 2 clinical trial** of SRSD107 for thromboembolic disorders[1](index=1&type=chunk)[10](index=10&type=chunk) [Regenerative Medicine Programs](index=4&type=section&id=Regenerative%20Medicine%20Programs) The company is advancing its regenerative medicine programs for Type 1 Diabetes, with an update on next-generation therapies expected in 2025 - Developing next-generation programs for Type 1 Diabetes (T1D) using iPSC-derived, allogeneic, gene-edited beta islet cell precursors to enable **insulin independence without immunosuppression**[9](index=9&type=chunk) - An update on the regenerative medicine programs is expected in **2025**[9](index=9&type=chunk) [Second Quarter 2025 Financial Results](index=5&type=section&id=Second%20Quarter%202025%20Financial%20Results) The company reported a net loss of $208.5 million for Q2 2025, driven by a one-time R&D expense, while maintaining a strong cash position of $1.72 billion [Financial Performance Summary](index=5&type=section&id=Financial%20Performance%20Summary) The company's cash position decreased to $1.72 billion, while net loss increased to $208.5 million due to a $96.3 million in-process R&D expense Q2 2025 Financial Highlights (vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | Change Driver | | :--- | :--- | :--- | :--- | | Cash Position (June 30) | $1,721.2M | N/A | Decrease from Dec 31, 2024 ($1,903.8M) due to operating expenses and Sirius payment | | R&D Expenses | $69.9M | $80.2M | Decrease in employee-related expenses | | Acquired In-Process R&D | $96.3M | $0 | Costs incurred from Sirius Agreement | | G&A Expenses | $18.9M | $19.5M | Remained relatively stable | | Collaboration Expense, net | $45.2M | $52.1M | Decrease due to higher CASGEVY revenue and lower program expenses | | Net Loss | ($208.5M) | ($126.4M) | Increased primarily due to acquired in-process R&D expense | [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q2 2025, the company reported total revenues of $0.89 million and a net loss of $208.5 million, or ($2.40) per share Condensed Consolidated Statements of Operations (Unaudited, In thousands) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Total revenue** | **$892** | **$517** | **$1,757** | **$1,021** | | Research and development | $69,894 | $80,165 | $142,378 | $156,338 | | Acquired in-process R&D | $96,253 | $— | $96,253 | $— | | General and administrative | $18,916 | $19,481 | $38,212 | $37,434 | | Collaboration expense, net | $45,153 | $52,131 | $102,662 | $99,097 | | **Total operating expenses** | **$230,216** | **$151,777** | **$379,505** | **$292,869** | | **Loss from operations** | **($229,324)** | **($151,260)** | **($377,748)** | **($291,848)** | | **Net loss** | **($208,549)** | **($126,408)** | **($344,545)** | **($242,999)** | | **Net loss per common share — basic** | **($2.40)** | **($1.49)** | **($3.98)** | **($2.92)** | [Condensed Consolidated Balance Sheets Data](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20Data) As of June 30, 2025, the company held $1.72 billion in cash and marketable securities, with total assets of $2.03 billion Condensed Consolidated Balance Sheets Data (Unaudited, in thousands) | | As of June 30, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $193,618 | $298,257 | | Marketable securities | $1,527,619 | $1,605,569 | | Working capital | $1,629,304 | $1,849,350 | | Total assets | $2,029,711 | $2,242,034 | | Total shareholders' equity | $1,711,125 | $1,932,080 |

Core Insights - CRISPR Therapeutics is experiencing significant momentum in both commercial and clinical programs, particularly with the activation of over 75 authorized treatment centers for CASGEVY, which has led to approximately 115 patients having cells collected globally [1][2][3] - The company is advancing multiple clinical trials, including CTX310 targeting ANGPTL3, which has shown promising preliminary data with reductions of up to 82% in triglycerides and 86% in LDL [1][3][7] - CRISPR Therapeutics has a strong financial position with approximately $1.7 billion in cash and marketable securities as of June 30, 2025, despite a net loss of $208.5 million for the second quarter of 2025 [1][14][29] Commercial Programs - CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, is approved in multiple regions including the U.S., EU, and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia [3][12] - The company has achieved its target of activating 75 authorized treatment centers globally, with 29 patients having received infusions of CASGEVY, including 16 in the second quarter of 2025 [1][3] - Reimbursement agreements have been secured in 10 countries, enhancing patient access to CASGEVY [3] Clinical Trials - Ongoing clinical trials for CTX310™ are expected to present complete Phase 1 data in the second half of 2025, with preliminary results indicating significant reductions in triglycerides and LDL [1][3][7] - CTX320™ is in a Phase 1 trial targeting the LPA gene, with updates anticipated in the first half of 2026 [1][3] - CTX112™ and CTX131™ are also in clinical trials targeting CD19 and CD70, respectively, with broad updates expected in the second half of 2025 [1][3][7] Financial Performance - For the second quarter of 2025, CRISPR Therapeutics reported a net loss of $208.5 million, compared to a net loss of $126.4 million in the same period of 2024 [14][29] - Research and development expenses decreased to $69.9 million from $80.2 million year-over-year, primarily due to reduced employee-related costs [14][29] - The total operating expenses for the second quarter were $230.2 million, up from $151.8 million in the previous year, largely due to acquired in-process R&D expenses related to the Sirius Agreement [14][29] Strategic Collaborations - A strategic collaboration with Sirius Therapeutics was established to develop and commercialize small interfering RNA (siRNA) therapies, starting with SRSD107 for thromboembolic disorders [13][20] - The European Medicines Agency has authorized a Phase 2 clinical trial for SRSD107, which aims to evaluate its safety and efficacy in preventing postoperative venous thromboembolism [13][20]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2][5] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, reliance solely on brokerage recommendations may not be advisable, as studies suggest they often fail to guide investors effectively towards stocks with high price appreciation potential [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, often resulting in a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is presented in whole numbers and is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics has declined by 1.4% over the past month to -$5.61, indicating growing pessimism among analysts regarding the company's earnings prospects [14][15] Group 3 - The recent change in the consensus estimate, along with other earnings-related factors, has led to a Zacks Rank of 4 (Sell) for CRISPR Therapeutics, suggesting caution despite the favorable ABR [15] - The ABR may not always reflect the most current information, while the Zacks Rank is updated more frequently to reflect changes in earnings estimates [13]

Company Overview - CRISPR Therapeutics AG (CRSP) is expected to report a quarterly loss of $1.47 per share, reflecting a year-over-year change of +1.3% [3] - Revenues are anticipated to be $6.58 million, representing a significant increase of 1165.4% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 1.75% lower over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for CRISPR Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -11.09% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10] - CRISPR Therapeutics currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, CRISPR Therapeutics was expected to post a loss of $1.27 per share but actually reported a loss of -$1.58, resulting in a surprise of -24.41% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - Another player in the biomedical and genetics industry, Illumina (ILMN), is expected to post earnings of $1.02 per share, indicating a year-over-year change of +183.3% [18] - Illumina's revenues are projected to be $1.05 billion, down 5.8% from the previous year, with a slight downward revision of 0.2% in the consensus EPS estimate over the last 30 days [19]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, caution is advised as studies show limited success of brokerage recommendations in predicting stock price increases [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with five Strong Buy recommendations for every Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is highlighted as a more reliable indicator of near-term price performance, based on earnings estimate revisions [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$5.54, suggesting the stock may perform in line with the broader market [13][14] Group 3 - The Zacks Rank for CRISPR Therapeutics is currently 3 (Hold), indicating a more cautious stance compared to the Buy-equivalent ABR [14] - The ABR is not always up-to-date, while the Zacks Rank reflects timely earnings estimate revisions, making it a more current indicator of future price movements [12]